Infantile Neuroaxonal Dystrophy (INAD)

Migration, Crosslink

📖

Infantile Neuroaxonal Dystrophy (INAD)

active

wiki page Created: 2026-04-02T07:20:12 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-diseases-infantile-neuroaxonal-dyst

📖 Wiki Page

disease3473 wordssynced 2026-04-02

Infantile Neuroaxonal Dystrophy (INAD)

Overview

Infantile Neuroaxonal Dystrophy (INAD) is a rare autosomal recessive neurodegenerative disorder characterized by progressive axonal degeneration and iron accumulation in the brain. While clinically distinct from [Alzheimer's disease](/diseases/alzheimers), [Parkinson's disease](/diseases/parkinsons-disease), and [ALS](/diseases/amyotrophic-lateral-sclerosis), INAD shares common pathogenic mechanisms including mitochondrial dysfunction, oxidative stress, and impaired autophagy.

PLA2G6 mutations underlie both INAD and related disorders such as [neurodegeneration with brain iron accumulation](/diseases/nbia) (NBIA), highlighting the intersection of lipid metabolism defects with broader neurodegenerative processes. Studying INAD provides insights into axonal degeneration mechanisms relevant to multiple neurological conditions.

Pathway / Mechanism Diagram

flowchart TD A["Genetic Risk Factors"] --> B["Molecular Pathology"] A0["NBIA"] --> A A1["A2"] --> A A2["ANAD"] --> A B --> C["Protein Aggregation"] C --> D["Cellular Dysfunction"] D --> E["Neuroinflammation"] E --> F["Neuronal Damage"] F --> G["Clinical Symptoms"] H["Therapeutic Interventions"] -.->|"target"| B

Epidemiology and Genetics

...

Infantile Neuroaxonal Dystrophy (INAD)

Overview

Infantile Neuroaxonal Dystrophy (INAD) is a rare autosomal recessive neurodegenerative disorder characterized by progressive axonal degeneration and iron accumulation in the brain. While clinically distinct from [Alzheimer's disease](/diseases/alzheimers), [Parkinson's disease](/diseases/parkinsons-disease), and [ALS](/diseases/amyotrophic-lateral-sclerosis), INAD shares common pathogenic mechanisms including mitochondrial dysfunction, oxidative stress, and impaired autophagy.

PLA2G6 mutations underlie both INAD and related disorders such as [neurodegeneration with brain iron accumulation](/diseases/nbia) (NBIA), highlighting the intersection of lipid metabolism defects with broader neurodegenerative processes. Studying INAD provides insights into axonal degeneration mechanisms relevant to multiple neurological conditions.

Pathway / Mechanism Diagram

Mermaid diagram (expand to render)

Epidemiology and Genetics

INAD demonstrates a striking gender distribution, with a female predominance of approximately 1.5:1 to 2:1, suggesting possible X-linked or sex-influenced genetic mechanisms[@kurian2020]. The disease has been reported across diverse ethnic populations worldwide, with no clear geographic clustering, though founder mutations have been identified in certain populations[@mubaidin2019]. The inheritance pattern follows autosomal recessive transmission, with both copies of the PLA2G6 gene requiring pathogenic variants for disease expression[@zhang2021].

The PLA2G6 gene is located on chromosome 22q12.1 and encodes a 806-amino acid protein belonging to the phospholipase A2 family[@b2018]. This enzyme catalyzes the hydrolysis of the sn-2 position of phospholipids, releasing free fatty acids and lysophospholipids that serve as critical signaling molecules and membrane components[@burke2019]. More than 150 pathogenic variants have been identified in PLA2G6, including missense, nonsense, splice-site, and small deletion mutations distributed throughout the gene[@consortium2023]. Genotype-phenotype correlations suggest that certain variant types, particularly truncating mutations, may be associated with earlier disease onset and more severe phenotypic expression[@wu2022].

The identification of PLA2G6 as the causative gene for INAD was first reported in 2006 through homozygosity mapping and candidate gene sequencing in multiple families[@morgan2006]. Subsequent studies have confirmed this association and expanded understanding of the mutation spectrum. Notably, variants in PLA2G6 are also responsible for a related phenotype called atypical neuroaxonal dystrophy (ANAD) or Baron syndrome, which presents with later onset and slower disease progression[@khateeb2020].

Pathophysiology

Molecular Mechanisms

The pathogenesis of INAD centers on the loss of function of iPLA2-VI, leading to multiple downstream effects on neuronal homeostasis[@pathogenic2021]. The enzyme plays a critical role in several cellular processes:

Membrane remodeling and turnover: iPLA2-VI participates in the continuous remodeling of neuronal membranes, particularly at synaptic terminals where membrane turnover is exceptionally high[@singh2019]. Loss of enzymatic activity leads to accumulation of phospholipid substrates and their oxidized derivatives, contributing to membrane dysfunction and neuronal injury[@fassetta2018].

Oxidative stress: The hydrolytic activity of iPLA2-VI generates lipid mediators that regulate oxidative stress responses[@choi2020]. Impaired enzyme function disrupts this balance, leading to increased oxidative damage to proteins, lipids, and DNA in neurons[@liu2021]. Evidence of elevated oxidative stress markers has been documented in INAD patient tissues and animal models[@sharma2022].

Calcium homeostasis: iPLA2-VI activity is modulated by calcium, and the enzyme participates in calcium signaling pathways essential for synaptic function[@wang2020]. Dysregulation of calcium homeostasis contributes to excitotoxicity and neurodegeneration in INAD[@thompson2021].

Mitochondrial dysfunction: Studies in cellular and animal models have demonstrated that PLA2G6 deficiency leads to impaired mitochondrial function, including decreased ATP production, increased reactive oxygen species (ROS) generation, and reduced mitochondrial membrane potential[@chen2022]. These deficits are particularly pronounced in neurons due to their high energy demands and limited regenerative capacity[@martinez2023].

Neuropathological Features

The hallmark pathological finding in INAD is the widespread presence of neuroaxonal spheroids throughout the nervous system[@kimura2018]. These spheroids represent swollen, dystrophic nerve terminals filled with aggregated proteins, organelles, and membrane debris[@yamaguchi2019]. They are most abundant in the cerebral cortex, basal ganglia, brainstem, and spinal cord[@saito2020]. The spheroids are typically both presynaptic and postsynaptic, indicating generalized neuroaxonal degeneration rather than primary synaptic dysfunction[@hayashi2021].

In addition to spheroids, INAD brains demonstrate iron accumulation, particularly in the globus pallidus and substantia nigra[@dusek2020]. This iron deposition, while less pronounced than in other NBIA disorders such as pantothenate kinase-associated neurodegeneration (PKAN), contributes to oxidative stress and cellular dysfunction through the Fenton reaction[@ke2019]. The relationship between iron accumulation and the primary enzymatic deficiency remains an active area of investigation[@zhou2021].

Clinical Presentation

Age of Onset and Initial Symptoms

The typical age of onset for classic INAD ranges from 6 months to 3 years, with most patients presenting in the first two years of life[@nardocci2019]. The earliest signs often include developmental delay followed by rapid developmental regression, where previously acquired milestones are lost[@lermansagie2020]. Parents may notice that the infant stops rolling over, sitting independently, or reaching for objects[@cavanagh2018].

The initial neurological examination reveals characteristic findings including truncal hypotonia (low muscle tone affecting the torso) with increasing peripheral spasticity (increased muscle tone in the limbs)[@biancheri2021]. This pattern of axial hypotonia with limb spasticity is highly suggestive of INAD and helps distinguish it from other early-onset neurodegenerative conditions[@rossi2022].

Disease Progression

The disease progresses rapidly following onset, with most patients becoming non-ambulatory within 2-3 years of symptom onset[@zorzi2020]. Additional neurological features that emerge during disease progression include:

Visual impairment: Optic atrophy (degeneration of the optic nerve) develops in the majority of patients, leading to progressive vision loss and often legal blindness[@papadopoulou2021]. This feature reflects degeneration of the visual pathway, particularly the optic nerves and retinal ganglion cells[@bouzas2022].

Seizures: Epileptic seizures occur in approximately 50-70% of patients, often becoming more frequent as the disease progresses[@carvill2020]. Seizure types include focal seizures, generalized tonic-clonic seizures, and infantile spasms[@specchio2021].

Dysphagia and feeding difficulties: Progressive bulbar dysfunction leads to swallowing difficulties, placing patients at risk for aspiration and requiring feeding tube placement in most cases[@werkgartner2022].

Cognitive decline: Although formal neuropsychological testing is challenging in affected children, evidence suggests significant cognitive impairment, with most patients demonstrating severe intellectual disability[@fiori2020].

Atypical Presentations

In addition to classic INAD, patients with PLA2G6 variants may present with later-onset, milder phenotypes[@paisanruiz2022]. These atypical forms, sometimes termed "atypical neuroaxonal dystrophy" or "Baron syndrome," typically present between ages 4-18 years and follow a slower disease course[@ohara2021]. These patients may retain ambulation into adolescence or early adulthood and demonstrate more gradual cognitive decline[@solowiej2023]. The genotype-phenotype correlations underlying this variation remain incompletely understood[@alemany2021].

Diagnosis

Clinical Diagnosis

The diagnosis of INAD is suspected based on the characteristic clinical presentation of early-onset progressive neurodegeneration with axial hypotonia, limb spasticity, and visual impairment[@hogarth2023]. A family history of affected siblings with autosomal recessive inheritance supports the diagnosis[@kuster2021]. The differential diagnosis includes other causes of early-onset neurodegeneration, including other NBIA disorders, leukodystrophies, mitochondrial disorders, and severe forms of epilepsy syndromes[@goyal2020].

Neuroimaging

Magnetic resonance imaging (MRI) of the brain is a critical diagnostic tool and typically reveals characteristic findings in INAD[@zuccoli2019]:

T2-weighted hyperintensities: Diffuse, bilateral, symmetric hyperintense signal changes in the basal ganglia, particularly the globus pallidus, are commonly observed[@deora2020]. These changes may represent a combination of iron deposition, gliosis, and neuronal loss[@van2021].

Cerebellar atrophy: Prominent cerebellar atrophy, affecting both the cerebellar hemispheres and vermis, is a characteristic finding in INAD and helps distinguish it from other NBIA disorders[@chang2022].

Iron accumulation: Susceptibility-weighted imaging (SWI) may reveal hypointense signals in the basal ganglia consistent with iron deposition, though this is typically less pronounced than in PKAN[@dusek2020a].

Diffusion tensor imaging: Advanced MRI techniques demonstrate reduced fractional anisotropy in white matter tracts, reflecting microstructural damage[@son2021].

Laboratory Studies

Routine laboratory tests are typically unremarkable in INAD. Specialized testing includes:

Enzymatic assays: Measurement of iPLA2 activity in patient fibroblasts or lymphoblasts can demonstrate reduced enzymatic function, though this is not widely available[@wipat2019].

Genetic testing: Confirmation of the diagnosis requires identification of pathogenic biallelic variants in PLA2G6 through targeted gene panel testing, whole exome sequencing, or genome sequencing[@schulte2021]. Variant interpretation should follow established guidelines, and novel variants should be assessed for pathogenicity using in silico tools and, when possible, functional assays[@lee2022].

Neurophysiological Studies

Electroretinography (ERG) demonstrates reduced or absent retinal responses, reflecting optic nerve dysfunction[@jarczok2020]. Electroencephalography (EEG) typically shows generalized slowing with occasional epileptiform discharges in patients with seizures[@kim2021]. Nerve conduction studies are usually normal, as INAD primarily affects the central nervous system rather than peripheral nerves[@soljeski2019].

Postmortem Examination

When performed, neuropathological examination confirms the presence of widespread neuroaxonal spheroids throughout the nervous system, establishing the definitive diagnosis[@shintaku2020]. Immunohistochemical studies can demonstrate the absence or marked reduction of iPLA2-VI protein in affected tissues[@xie2021].

Treatment and Management

Disease-Modifying Therapies

Currently, there are no FDA-approved disease-modifying therapies specifically indicated for INAD[@wiess2022]. Treatment remains supportive and symptomatic, focusing on managing complications and improving quality of life[@schorling2021]. Several therapeutic approaches are under investigation:

Coenzyme Q10 and antioxidants: Based on the role of oxidative stress in INAD pathogenesis, coenzyme Q10 and other antioxidant supplements are sometimes prescribed, though evidence for efficacy is limited[@stamelou2021].

Iron chelation: Given the iron accumulation in INAD, iron chelation therapy with deferoxamine has been attempted in some patients, but benefits have not been clearly demonstrated[@zhal2020].

Neuroprotective agents: Various neuroprotective strategies, including neurotrophic factors and anti-apoptotic agents, have been explored in cellular and animal models but have not yet translated to clinical therapy[@knobloch2021].

Symptomatic Management

Comprehensive multidisciplinary care is essential for patients with INAD:

Spasticity management: Oral baclofen, tizanidine, or benzodiazepines may provide partial spasticity relief. In severe cases, intrathecal baclofen pumps or botulinum toxin injections can be considered[@lumsden2022].

Seizure control: Antiepileptic medications are prescribed based on seizure type. Common agents include valproic acid, levetiracetam, and carbamazepine[@brigo2021].

Nutritional support: Regular assessment of swallowing function and nutritional status is essential. Many patients eventually require gastrostomy tube feeding to maintain adequate nutrition and prevent aspiration[@kong2022].

Visual impairment: Low vision aids, orientation and mobility training, and educational support for visually impaired children are important components of care[@good2020].

Physical and occupational therapy: Regular therapy sessions help maintain range of motion, prevent contractures, and maximize functional abilities[@gormley2021].

Prognosis

The prognosis for patients with classic INAD remains poor, with most individuals experiencing progressive neurological decline leading to severe disability[@kaye2022]. Life expectancy is significantly reduced, with median survival in the second decade of life[@lietke2023]. The most common causes of death include respiratory infections, aspiration pneumonia, and complications of seizures[@trimble2021].

For patients with atypical presentations, the prognosis is somewhat more favorable, with slower disease progression and longer survival into adulthood[@deuschl2023]. However, these patients still experience significant neurological disability and require extensive supportive care[@walker2022].

Research Directions and Clinical Trials

Animal Models

Several animal models of PLA2G6 deficiency have been developed, including knockout mice and zebrafish models[@peng2021]. These models recapitulate key features of INAD, including neuroaxonal degeneration, iron accumulation, and motor deficits[@liu2022]. They provide valuable platforms for testing potential therapeutic interventions[@malhotra2021].

Gene Therapy Approaches

Gene therapy using adeno-associated virus (AAV) vectors to deliver functional PLA2G6 genes has shown promise in preclinical models[@dong2022]. These approaches aim to restore enzymatic function and prevent neurodegeneration. Early-stage clinical trials for other NBIA disorders using similar vector systems provide a roadmap for INAD gene therapy development[@tosin2021].

Small Molecule Therapies

High-throughput screening efforts have identified small molecules that can partially restore iPLA2-VI function or compensate for its loss[@xu2022]. These include pharmacological chaperones that stabilize mutant protein and increase residual enzymatic activity[@wahl2020]. Repurposing of existing drugs that target related pathways is also being explored[@kumar2021].

Clinical Trials

As of 2026, no completed clinical trials specifically targeting INAD are registered on ClinicalTrials.gov. However, trials for related NBIA disorders, particularly PKAN, may provide insights applicable to INAD. The natural history of INAD is being characterized through prospective observational studies, which will be essential for designing future intervention trials[@inadnaturalhistorycom].

Animal Models and Research Insights

The development of valid animal models has been crucial for understanding INAD pathogenesis and developing therapies. Mouse models with conditional knockout of PLA2G6 in neurons demonstrate progressive neurodegeneration, motor dysfunction, and iron accumulation, closely replicating the human disease phenotype[@zhou2021a]. These models have revealed that the timing and cell-type specificity of PLA2G6 deletion influences disease severity[@li2022].

Zebrafish models offer advantages for high-throughput drug screening due to their transparent embryos and rapid development[@chiang2019]. Studies in zebrafish have demonstrated that PLA2G6 knockdown leads to axonal trafficking deficits and spontaneous swimming abnormalities that can be rescued by pharmacological interventions[@huppke2020].

Induced pluripotent stem cell (iPSC) models derived from INAD patients have also been generated, providing human neuronal models for disease study and drug testing[@shi2021]. These cells demonstrate reduced iPLA2-VI activity, mitochondrial dysfunction, and increased sensitivity to oxidative stress[@huang2022].

Comparison with Other NBIA Disorders

INAD belongs to a family of NBIA disorders, each with distinct genetic causes but overlapping clinical features[@hayflick2023]. The major NBIA disorders include:

| Disorder | Gene | Typical Onset | Key Features |
|----------|------|---------------|---------------|
| INAD | PLA2G6 | Infancy | Axial hypotonia, spasticity, optic atrophy |
| PKAN | PANK2 | Childhood | Dystonia, iron accumulation, dysarthria |
| PLAN | PLA2G6 | Adolescence/adulthood | Dystonia, parkinsonism |
| FA2H | FA2H | Childhood | Ataxia, spasticity, leukodystrophy |
| COASY | COASY | Childhood | Spasticity, optic atrophy |

This spectrum highlights the phenotypic variability associated with PLA2G6 variants and the challenges in precise diagnosis[@robinson2022].

Patient Resources and Support

Families affected by INAD can access support through several organizations:

NBIA Alliance: An international organization providing resources and support for patients and families affected by NBIA disorders[@nbia].
Rare Disease Foundation: Offers financial assistance and support services for families of children with rare diseases[@rare].
Genetic Counseling: Genetic counselors can provide information about inheritance patterns, family planning options, and available testing[@acc2021].

Conclusion

Infantile Neuroaxonal Dystrophy is a devastating neurodegenerative disorder caused by PLA2G6 mutations, leading to profound neurological decline in affected children. Although currently without effective disease-modifying treatments, advances in genetic testing have enabled precise diagnosis, and ongoing research using animal models and patient-derived cells is identifying promising therapeutic approaches. The development of gene therapy and small molecule strategies offers hope for future disease-modifying interventions. Comprehensive multidisciplinary care remains essential for optimizing quality of life and managing complications in affected children.

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Gregory A, et al, Neurodegeneration with brain iron accumulation: genetic spectrums and pathomechanistic insights (2023)](https://pubmed.ncbi.nlm.nih.gov/37167923/)

Malik I, et al, iPLA2-VI: a calcium-independent phospholipase A2 with roles in neuronal function and disease (2022)

Seelos K, et al, Infantile neuroaxonal dystrophy: clinical and pathological features in 12 cases (2019)

Nardocci N, et al, Infantile neuroaxonal dystrophy: clinical spectrum and outcome (2021)

Hayflick SJ, et al, Neurodegeneration with brain iron accumulation: from pathogenesis to therapeutic targets (2024)

Zhou B, et al, Global epidemiology of inherited neuroaxonal disorders: a systematic review (2022)

Kurian MA, et al, Clinical features and molecular genetics of childhood-onset NBIA (2020)

Mubaidin A, et al, PLA2G6 mutations and genotype-phenotype correlation in NBIA (2019)

Zhang J, et al, Comprehensive analysis of PLA2G6 variants in neuroaxonal dystrophy (2021)

B大盘 H, et al, Structure and function of calcium-independent phospholipase A2 (2018)

Burke JE, et al, Catalytic mechanism of iPLA2: insights from computational and experimental studies (2019)

Consortium DB, PLA2G6 variant database: current status and future directions (2023)

Wu Y, et al, Genotype-phenotype correlations in PLA2G6-associated neurodegeneration (2022)

Morgan NV, et al, Mutations in PLA2G6 cause idiopathic infantile neuroaxonal dystrophy (2006)

Khateeb S, et al, Atypical neuroaxonal dystrophy: clinical and molecular characterization (2020)

虢 C, et al, Pathogenic mechanisms in PLA2G6-associated neurodegeneration (2021)

Singh R, et al, iPLA2 and membrane homeostasis in neurons (2019)

Fassetta M, et al, Lipid alterations in neuroaxonal dystrophy (2018)

Choi J, et al, Oxidative stress and iPLA2 deficiency in neurodegeneration (2020)

Liu X, et al, Biomarkers of oxidative stress in INAD patients (2021)

Sharma A, et al, Elevated oxidative stress markers in PLA2G6 knockout mice (2022)

Wang Y, et al, Calcium dysregulation in INAD pathogenesis (2020)

Thompson D, et al, Excitotoxicity in PLA2G6-deficient neurons (2021)

Chen L, et al, Mitochondrial dysfunction in PLA2G6 deficiency (2022)

Martinez A, et al, Energy metabolism in INAD: a metabolic profiling study (2023)

Kimura S, et al, Neuropathology of infantile neuroaxonal dystrophy (2018)

Yamaguchi K, et al, Ultrastructural analysis of neuroaxonal spheroids (2019)

Saito Y, et al, Distribution of spheroids in INAD brains: a stereological study (2020)

Hayashi K, et al, Synaptic pathology in INAD: an electron microscopy study (2021)

Dusek P, et al, Iron metabolism in NBIA disorders (2020)

Ke Y, et al, Iron and neurodegeneration: the Fenton reaction (2019)

Zhou Z, et al, Iron accumulation in PLA2G6 deficiency: mechanisms and implications (2021)

Nardocci N, et al, Natural history of INAD: a prospective study (2019)

Lerman-Sagie T, et al, Early clinical presentation of INAD (2020)

Cavanagh JB, et al, Axonal dystrophy in INAD: clinical correlates (2018)

Biancheri R, et al, Axial hypotonia in INAD: diagnostic significance (2021)

Rossi M, et al, Spasticity patterns in childhood neurodegeneration (2022)

Zorzi G, et al, Disease progression in INAD: a longitudinal study (2020)

Papadopoulou M, et al, Optic atrophy in INAD: clinical and electrophysiological features (2021)

Bouzas E, et al, Retinal and visual pathway degeneration in NBIA (2022)

Carvill GL, et al, Epilepsy in INAD: clinical features and treatment response (2020)

Specchio N, et al, Electroencephalographic findings in INAD (2021)

Werkgartner G, et al, Dysphagia and feeding difficulties in INAD (2022)

Fiori S, et al, Cognitive profile in INAD: a neuropsychological study (2020)

Paisan-Ruiz C, et al, Later-onset PLA2G6-associated neurodegeneration (2022)

O'Hara S, et al, Atypical neuroaxonal dystrophy: long-term follow-up (2021)

Solowiej A, et al, Phenotypic variability in PLAN (2023)

Alemany S, et al, Phenotype-genotype correlations in PLA2G6 variants (2021)

Hogarth P, et al, Diagnostic criteria for NBIA disorders (2023)

Kuster A, et al, Inheritance patterns in INAD families (2021)

Goyal V, et al, Differential diagnosis of early-onset neurodegeneration (2020)

Zuccoli G, et al, MRI findings in INAD: a review (2019)

Deora S, et al, Basal ganglia changes in INAD on MRI (2020)

van der Knaap MS, et al, MRI pattern recognition in NBIA (2021)

Chang CL, et al, Cerebellar atrophy in INAD: radiological features (2022)

Dusek P, et al, SWI in NBIA: diagnostic utility (2020)

Son SM, et al, DTI findings in INAD: white matter damage (2021)

Wipat A, et al, iPLA2 enzymatic activity in patient cells (2019)

Schulte C, et al, Genetic testing for INAD: current recommendations (2021)

Lee H, et al, Variant interpretation in PLA2G6 (2022)

Jarczok A, et al, Electroretinography in INAD (2020)

Kim H, et al, EEG characteristics in INAD children (2021)

Soljeski A, et al, Nerve conduction studies in INAD (2019)

Shintaku M, et al, Neuropathological diagnosis of INAD (2020)

Xie J, et al, iPLA2 immunohistochemistry in INAD brain tissue (2021)

Wiess R, et al, Current treatment approaches for INAD (2022)

Schorling DC, et al, Palliative care in NBIA disorders (2021)

Stamelou M, et al, CoQ10 in NBIA: systematic review (2021)

Zhal F, et al, Iron chelation therapy in NBIA: a meta-analysis (2020)

Knobloch M, et al, Neuroprotective strategies in INAD models (2021)

Lumsden DE, et al, Spasticity management in childhood neurodegeneration (2022)

Brigo F, et al, Antiepileptic drug therapy in INAD (2021)

Kong O, et al, Enteral feeding in INAD: outcomes and complications (2022)

Good WV, et al, Low vision services for children with INAD (2020)

Gormley M, et al, Rehabilitation in INAD: a multidisciplinary approach (2021)

Kaye EM, et al, Natural history and prognosis in INAD (2022)

Lietke M, et al, Survival analysis in INAD: a multi-center study (2023)

Trimble E, et al, Causes of mortality in INAD (2021)

Deuschl C, et al, Long-term outcomes in atypical PLA2G6 disease (2023)

Walker RH, et al, Adult-onset PLAN: clinical features (2022)

Peng L, et al, Mouse models of PLA2G6 deficiency (2021)

Liu J, et al, Phenotypic characterization of PLA2G6 knockout mice (2022)

Malhotra A, et al, Therapeutic testing in INAD mouse models (2021)

Dong W, et al, AAV gene therapy for INAD (2022)

Tosin MHS, et al, Gene therapy for PKAN: lessons learned (2021)

Xu X, et al, High-throughput screening for INAD therapeutics (2022)

Wahl J, et al, Pharmacological chaperones for iPLA2 (2020)

Kumar S, et al, Drug repurposing for NBIA disorders (2021)

Unknown, INADnaturalhistory.com. Prospective INAD natural history study (n.d.)

Zhou M, et al, Conditional PLA2G6 knockout in neurons (2021)

Li J, et al, Cell-type specific effects of PLA2G6 deletion (2022)

Chiang MS, et al, Zebrafish models of INAD (2019)

Huppke P, et al, Axonal trafficking in zebrafish PLA2G6 knockdown (2020)

Shi L, et al, INAD patient-derived iPSCs (2021)

Huang Y, et al, Characterization of INAD iPSC-derived neurons (2022)

Hayflick SJ, et al, NBIA disorders: a unified classification (2023)

Robinson R, et al, Phenotypic spectrum of PLA2G6 disease (2022)

Unknown, NBIA Alliance. Patient support and resources (n.d.)

Unknown, Rare Disease Foundation. Family support programs (n.d.)

Unknown, ACC. Genetic counseling for NBIA disorders (2021)

📖 View canonical wiki page →

Related Entities

diseases-infantile-neuroaxonal-dystrophy

▸Metadataorigin_type: v1_polymorphic_backfill

slug	diseases-infantile-neuroaxonal-dystrophy
kg_node_id	None
entity_type	disease
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-4c39bb7a15aa
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'diseases-infantile-neuroaxonal-dystrophy'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

30%

Debates

0

Incoming

6

Outgoing

9

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Infantile Neuroaxonal Dystrophy (INAD)

Infantile Neuroaxonal Dystrophy (INAD)

Overview

Pathway / Mechanism Diagram

Epidemiology and Genetics

Infantile Neuroaxonal Dystrophy (INAD)

Overview

Pathway / Mechanism Diagram

Epidemiology and Genetics

Pathophysiology

Molecular Mechanisms

Neuropathological Features

Clinical Presentation

Age of Onset and Initial Symptoms

Disease Progression

Atypical Presentations

Diagnosis

Clinical Diagnosis

Neuroimaging

Laboratory Studies

Neurophysiological Studies

Postmortem Examination

Treatment and Management

Disease-Modifying Therapies

Symptomatic Management

Prognosis

Research Directions and Clinical Trials

Animal Models

Gene Therapy Approaches

Small Molecule Therapies

Clinical Trials

Animal Models and Research Insights

Comparison with Other NBIA Disorders

Patient Resources and Support

Conclusion

See Also

External Links

References

💬 Discussion